Cizzle Biotechnology is setting new benchmarks in lung cancer screening with their innovative blood test, which utilizes the CIZ1B biomarker for early detection. Allan Syms discusses the significant advancements in a recent video, highlighting the key partnership in North America that ensures guaranteed revenue and collaboration with major cancer centers. Furthermore, the development of a finger-prick test aims to expand lung cancer screening, supported by non-dilutive funding to propel their reach into the UK and Europe.
Discover more about this transformative technology by watching the full video on our website.
Watch the Full Video: Cizzle Biotech’s Innovation in Lung Cancer Detection